2019
DOI: 10.1136/jmedgenet-2018-105872
|View full text |Cite
|
Sign up to set email alerts
|

Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report

Abstract: The vocabulary currently used to describe genetic variants and their consequences reflects many years of studying and discovering monogenic disease with high penetrance. With the recent rapid expansion of genetic testing brought about by wide availability of high-throughput massively parallel sequencing platforms, accurate variant interpretation has become a major issue. The vocabulary used to describe single genetic variants in silico, in vitro, in vivo and as a contributor to human disease uses terms in comm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
31
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
4
2
1

Relationship

2
5

Authors

Journals

citations
Cited by 35 publications
(31 citation statements)
references
References 44 publications
0
31
0
Order By: Relevance
“…While the transcription activation assay for BRCA1 does not seem to discriminate between variants with intermediate risks from variants associated with high risk,29 the BRCA2 homologous recombination (HR) assay may be able to distinguish high from moderate and low/neutral as suggested by functional assessment of variant p.Y3035S 30. For genes in which pathogenic variants are clearly associated with disease risk, a two-stage reporting system has been proposed, that is, the first stage would establish pathogenicity of the variant based on multiple criteria and the second stage would denote the likely severity or clinical consequence for that variant (high, moderate or low risk) 31. Capturing the full spectrum of risk associated with distinct pathogenic variants is a critical challenge for assay development and for reporting laboratories.…”
Section: The Spectrum Of Low-risk Moderate-risk and High-risk Allelementioning
confidence: 99%
“…While the transcription activation assay for BRCA1 does not seem to discriminate between variants with intermediate risks from variants associated with high risk,29 the BRCA2 homologous recombination (HR) assay may be able to distinguish high from moderate and low/neutral as suggested by functional assessment of variant p.Y3035S 30. For genes in which pathogenic variants are clearly associated with disease risk, a two-stage reporting system has been proposed, that is, the first stage would establish pathogenicity of the variant based on multiple criteria and the second stage would denote the likely severity or clinical consequence for that variant (high, moderate or low risk) 31. Capturing the full spectrum of risk associated with distinct pathogenic variants is a critical challenge for assay development and for reporting laboratories.…”
Section: The Spectrum Of Low-risk Moderate-risk and High-risk Allelementioning
confidence: 99%
“…Following this rationale, posterior probabilities of pathogenicity were not calculated for any variant with a combined LR between 0.5 and 2. Posterior probability of pathogenicity was calculated for a total of 734 variants, and classification assigned based on previously published cut‐offs proposed for the International Agency for Research into Cancer (IARC) five tier classification scheme (Plon et al, ), with some modification of terms used to describe tiers (Spurdle et al, ), namely: Class 5 Pathogenic, >0.99; Class 4 Likely Pathogenic, 0.95–0.99; Class 3 Uncertain, 0.05–0.949; Class 2 Likely Benign, 0.001–0.049; and Class 1 Benign, <0.001. The variant classifications, with breakdown of LR components and sources, have been submitted to the following databases for public display:…”
Section: Methodsmentioning
confidence: 99%
“…Posterior probability of pathogenicity was calculated for a total of 734 variants, and classification assigned based on previously published cut-offs proposed for the International Agency for Research into Cancer (IARC) five tier classification scheme (Plon et al, 2008), with some modification of terms used to describe tiers (Spurdle et al, 2019)…”
Section: Multifactorial Likelihood Analysismentioning
confidence: 99%
“…For example, in conditions where the mechanism involves gain of function, a variant may be damaging or deleterious to the organism but not to protein activity as measured in a functional assay. Establishing standardized language to describe assay readout is an important step to prevent the misinterpretation of published data and to reduce inter-laboratory discordance with respect to PS3/BS3 application [3,22].…”
Section: Recommendationmentioning
confidence: 99%
“…Further granular specifications should be used to describe the "functionally abnormal" impact (i.e., complete loss of function, partial loss of function/intermediate effect/hypomorphic, gain of function, dominant-negative) as outlined by Spurdle, et al [22]. The final assessment of the evidence should take into account both the functional effect in the assay and the mechanism of disease (see below).…”
Section: Recommendationmentioning
confidence: 99%